Get the Stockscreener App
47.89
1.34%
-1.36
Tarsus Pharmaceuticals Inc stock is traded at $47.89, with a volume of 275.77K.
It is down -1.34% in the last 24 hours and down -2.76% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$49.25
Open:
$49.22
24h Volume:
275.77K
Relative Volume:
0.48
Market Cap:
$2.03B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-10.32
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
-0.27%
1M Performance:
-2.76%
6M Performance:
+33.31%
1Y Performance:
+49.78%
1-Day Range:
$47.76
$49.36
1-Week Range:
$46.94
$50.30
52-Week Range:
$20.08
$57.28
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
47.89 | 2.03B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.65 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.24 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.39 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
229.65 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.36 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Learn to Evaluate (TARS) using the Charts - news.stocktradersdaily.com
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by JPMorgan Chase & Co. - Defense World
Midday Stock Roundup: Healthcare, medtech stocks tumble - Orange County Business Journal
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Vanguard Group Inc. - Defense World
Papulopustular Rosacea Market Expected to Experience Major Growth by 2034, According to DelveInsight | Sol-Gel Technologies, Galderma, CollaGenex Pharma, Tarsus Pharma, Pfizer - Barchart.com
KLP Kapitalforvaltning AS Invests $299,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Sei Investments Co. Purchases 12,689 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
HighTower Advisors LLC Invests $207,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Raymond James Financial Inc. Makes New $1.11 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
(TARS) Trading Report - news.stocktradersdaily.com
With Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) It Looks Like You'll Get What You Pay For - simplywall.st
Teacher Retirement System of Texas Has $438,000 Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Fastest-Growing Public Cos. Ride Healthcare Boom - Orange County Business Journal
Tarsus Pharmaceuticals CEO sells $300,000 in stock By Investing.com - Investing.com Canada
Swiss National Bank Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals CEO sells $300,000 in stock - Investing.com India
4,031 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Victory Capital Management Inc. - Defense World
Where are the Opportunities in (TARS) - news.stocktradersdaily.com
Tarsus Pharmaceuticals CFO Jeffrey Farrow sells $178,306 in stock By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals CEO Bobak Azamian sells $1.16 million in stock By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals chief commercial officer sells $505,856 in stock By Investing.com - Investing.com India
Tarsus Pharmaceuticals COO Neervannan Seshadri sells $363,141 in stock By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals’ general counsel sells shares worth $463,765 By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals CFO Jeffrey Farrow sells $178,306 in stock - Investing.com
Tarsus Pharmaceuticals’ general counsel sells $463,765 in stock - Investing.com India
Tarsus Pharmaceuticals CEO Bobak Azamian sells $1.16 million in stock - Investing.com
Tarsus Pharmaceuticals’ general counsel sells shares worth $463,765 - Investing.com
Tarsus Pharmaceuticals chief commercial officer sells $505,856 in stock - Investing.com
Tarsus Pharmaceuticals’ HR chief sells shares worth $321,323 - Investing.com
Tarsus Pharmaceuticals COO Neervannan Seshadri sells $363,141 in stock - Investing.com
Tarsus Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView
Tarsus Pharmaceuticals completes $134.8M stock offering By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals completes $134.8M stock offering - Investing.com India
Tarsus prices $125M stock offering - MSN
Tarsus Pharma dips after upsized $125 mln stock offering - TradingView
Tarsus Pharmaceuticals Prices Upsized $125 Million Equity Offering -March 13, 2025 at 03:44 am EDT - Marketscreener.com
Tarsus Pharmaceuticals launches $100 million stock offering - Investing.com Australia
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering - GlobeNewswire
Tarsus Secures Massive $125M Capital Raise as Investors Rush Into Upsized Offering - StockTitan
Tarsus Announces Pricing Of Upsized $125 Million Public Offering -March 12, 2025 at 09:50 pm EDT - Marketscreener.com
Tarsus Pharmaceuticals dips on planned $100 million equity raise - TradingView
Tarsus Pharmaceuticals launches $100 million stock offering By Investing.com - Investing.com Canada
Tarsus Announces Proposed $100.0 Million Public Offering - The Manila Times
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):